The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Humana (NYSE:HUM).
The investment seeks long-term capital appreciation.
The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector.
The average market capitalization across the PGIM Jennison Health Sciences C MF is 129.17B. The market cap for tickers in the group ranges from 5.07B to 524.29B. LLY holds the highest valuation in this group at 524.29B. The lowest valued company is APLS at 5.07B.
The average weekly volume growth across all stocks in the PGIM Jennison Health Sciences C MF was 26%. For the same stocks of the MF, the average monthly volume growth was 42% and the average quarterly volume growth was 14%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 48
P/E Growth Rating: 57
Price Growth Rating: 53
SMR Rating: 61
Profit Risk Rating: 44
Seasonality Score: -35 (-100 ... +100)